PTEN and small cell lung carcinoma: Thanks to the introduction of genomic and proteomic platforms, we will be increasingly able to understand the different molecular profilings of SCLC and to identify specific druggable targets, such as PTEN, FGFR1, SOX-2, PI3K, PARP and others.